NCT00706589

Aripiprazole in Children and Adolescents With Chronic Tic Disorder or Tourette's Disorder

A Randomized, Double-blind, Dose-adjustment, Placebo-controlled Study to Evaluate the Efficacy and Safety of Aripiprazole in Children and Adolescents With Chronic Tic Disorders or Tourette's Disorder

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 61 (actual)
• Sponsor: Korea Otsuka Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 6 Years – 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this trial is to demonstrate the efficacy and safety of aripiprazole in children and adolescents aged 6\~18 years with chronic tic disorders or Tourette's disorder

Conditions

• Chronic Motor or Vocal Tic Disorder
• Tourette's Disorder

Interventions

Type	Name	Description
DRUG	aripiprazole	Initial dose : 2mg, Maximum dose : 20mg
DRUG	placebo	Initial dose: 2mg, Maximum dose:20mg

Timeline

• Start date: 2008-10-01
• Primary completion: 2010-04-01
• Completion: 2010-04-01
• First posted: 2008-06-27
• Last updated: 2013-07-26
• Results posted: 2013-07-26

Locations

6 sites across 1 country: South Korea